肺癌患者血清TGF-β_1浓度检测及临床意义分析

Detection of serum TGF-β_1 levels in lung cancer patients and its clinical significance

目的探讨检测肺癌患者血清中转化生长因子β1(transforming growth factorβtype1,TGF-β1)的临床应用价值。方法收集98例肺癌患者血清标本及40例健康对照者血清标本,运用酶联免疫吸附试验(ELISA)检测两组标本血清TGF-β1浓度。分析二者之间的差异及其与肺癌患者临床特征之间的关系。结果肺癌患者的血清TGF-β1浓度明显高于健康对照者,差异有统计学意义(66 848 pg/mL±37 178 pg/mL vs 48 790 pg/mL±23 111 pg/mL,P<0.01);肺癌患者血清TGF-β1浓度与TNM分期,淋巴结转移,病理分型无相关性(P>0.05);手术前后,化疗前后血清TGF-β1浓度差异无统计学意义(P>0.05)。结论血清TGF-β1对肺癌的辅助诊断有一定的临床价值。

Objective To evaluate the clinical significance of serum TGF-β1 in the diagnosis of lung cancer. Methods The serum level of TGF-β1 was measured by enzyme-linked immunosorbent assay （ELISA） in 98 lung cancer patients and 40 healthy control individuals, then the relationships between serum TGF-β1 level and the clinical features of lung cancer was analyzed. Results The serum TGF-β1 level in lung cancer patients was significantly higher than that in healthy control individuals （66 848 pg/mL ± 37 178 pg/mL vs 48 790 pg/mL ± 23 111 pg/mL, P 〈 0. 01 ）. No associations were found between the serum TGF-β1 level and the histological type of lung cancer, TNM stages, and lymph node metastases （LNM）. The serum TGF- β1 levels showed no significant differences in lung cancers with or without surgery and chemotherapy. Conclusion The serum TGF-β1 levels may be served as a complementary diagnostic test in lung cancer.